Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group

Basit Öğe Kaydı
dc.authoridSahin, Gulizar/0000-0002-0409-2710
dc.authoridTunca, Onur/0000-0003-1958-7617
dc.authoridtatar, erhan/0000-0002-5068-4231
dc.authoridUzerk Kibar, Muge/0000-0002-0948-6583
dc.authoridCetinkaya, Hakki/0000-0001-9527-3885
dc.authoridOruc, Aysegul/0000-0002-0342-9692
dc.contributor.authorOruc, Aysegul
dc.contributor.authorSumnu, Abdullah
dc.contributor.authorTurkmen, Aydin
dc.contributor.authorBasturk, Taner
dc.contributor.authorCebeci, Egemen
dc.contributor.authorTurgutalp, Kenan
dc.contributor.authorCetinkaya, Hakki
dc.date.accessioned2025-02-22T14:08:57Z
dc.date.available2025-02-22T14:08:57Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackgroundImmunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye.MethodThe data of 1656 IgAN patients in the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases Study Group were analyzed. A total of 408 primary IgAN patients treated with IST (65.4% male, mean age 38.4 +/- 12.5 years, follow-up 30 (3-218) months) were included and divided into two groups according to treatment protocols (isolated corticosteroid [CS] 70.6% and combined IST 29.4%). Treatment responses, associated factors were analyzed.ResultsRemission (66.7% partial, 33.7% complete) was achieved in 74.7% of patients. Baseline systolic blood pressure, mean arterial pressure, and proteinuria levels were lower in responsives. Remission was achieved at significantly higher rates in the CS group (78% vs. 66.7%, p = 0.016). Partial remission was the prominent remission type. The remission rate was significantly higher among patients with segmental sclerosis compared to those without (60.4% vs. 49%, p = 0.047). In the multivariate analysis, MEST-C S1 (HR 1.43, 95% CI 1.08-1.89, p = 0.013), MEST-C T1 (HR 0.68, 95% CI 0.51-0.91, p = 0.008) and combined IST (HR 0.66, 95% CI 0.49-0.91, p = 0.009) were found to be significant regarding remission.ConclusionCS can significantly improve remission in high-risk Turkish IgAN patients, despite the reliance on non-quantitative endpoints for favorable renal outcomes. Key predictors of remission include baseline proteinuria and specific histological markers. It is crucial to carefully weigh the risks and benefits of immunosuppressive therapy for these patients.en_US
dc.identifier.doi10.1080/0886022X.2024.2341787
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue1en_US
dc.identifier.pmid38637275en_US
dc.identifier.scopus2-s2.0-85190809699en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1080/0886022X.2024.2341787
dc.identifier.urihttps://hdl.handle.net/11468/29724
dc.identifier.volume46en_US
dc.identifier.wosWOS:001205022800001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectIgA nephropathyen_US
dc.subjectimmunosuppressive treatmenten_US
dc.subjectTurkiyeen_US
dc.subjectremissionen_US
dc.subjectoutcomeen_US
dc.titleImmunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu